197369-11-2

Basic information

• Product Name: 1,3-Benzodioxole-5-acetic acid, 6-(4-methoxybenzoyl)-, methyl ester
• Synonyms: 1,3-Benzodioxole-5-acetic acid,6-(4-methoxybenzoyl)-,methyl ester;methyl 2-[2-(4-methoxybenzoyl)-4,5-methylenedioxyphenyl]acetate;methyl 4,5-methylenedioxy-2-(4-methoxybenzoyl)phenylacetate;methyl 2-(4-methoxybenzoyl)-4,5-methylenedioxyphenylacetate;2-(4-methoxy-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester
• CAS NO: 197369-11-2
• Molecular Formula: C18H16O6
• Molecular Weight: 328.321
• Mol File: 197369-11-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1,3-Benzodioxole-5-acetic acid, 6-(4-methoxybenzoyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzodioxole-5-acetic acid, 6-(4-methoxybenzoyl)-, methyl ester(197369-11-2)
• EPA Substance Registry System: 1,3-Benzodioxole-5-acetic acid, 6-(4-methoxybenzoyl)-, methyl ester(197369-11-2)

Safety Data

• Hazardous Substances Data: 197369-11-2(Hazardous Substances Data)

Upstream product

• 326-59-0 benzo[1,3]dioxol-5-yl-acetic acid methyl ester 
• 100-09-4 4-methoxybenzoic acid 
• 100-07-2 4-methoxy-benzoyl chloride 

Downstream Products

• 1192235-13-4 [4,5-dihydroxy-2-(4-methoxybenzoyl)-phenyl]acetic acid 

Relevant articles and documents

Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors

A series of 1-aryl-6,7-disubstituted-2H-isoquinolin-3-ones (2-10) was synthesized and evaluated for their inhibition against Plasmodium falciparum cysteine protease falcipain-2, as well as against cultured P. falciparum strain FCBR parasites. All compound

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.